ES2114570T3 - Utilizacion de derivados de prostaciclina para la inhibicion o el tratamiento de trastornos de la microcirculacion en el caso de la toma de agentes de contraste por rayos x, resonancia magnetica nuclear o ultrasonidos. - Google Patents

Utilizacion de derivados de prostaciclina para la inhibicion o el tratamiento de trastornos de la microcirculacion en el caso de la toma de agentes de contraste por rayos x, resonancia magnetica nuclear o ultrasonidos.

Info

Publication number
ES2114570T3
ES2114570T3 ES92922216T ES92922216T ES2114570T3 ES 2114570 T3 ES2114570 T3 ES 2114570T3 ES 92922216 T ES92922216 T ES 92922216T ES 92922216 T ES92922216 T ES 92922216T ES 2114570 T3 ES2114570 T3 ES 2114570T3
Authority
ES
Spain
Prior art keywords
prostacicline
ultrasonics
inhibition
rays
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92922216T
Other languages
English (en)
Spanish (es)
Inventor
Rainer Klopp
Wolfgang Niemer
Wolfgang Schippel
Werner Krause
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Application granted granted Critical
Publication of ES2114570T3 publication Critical patent/ES2114570T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
ES92922216T 1991-10-22 1992-10-22 Utilizacion de derivados de prostaciclina para la inhibicion o el tratamiento de trastornos de la microcirculacion en el caso de la toma de agentes de contraste por rayos x, resonancia magnetica nuclear o ultrasonidos. Expired - Lifetime ES2114570T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4135193A DE4135193C1 (enrdf_load_stackoverflow) 1991-10-22 1991-10-22

Publications (1)

Publication Number Publication Date
ES2114570T3 true ES2114570T3 (es) 1998-06-01

Family

ID=6443371

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92922216T Expired - Lifetime ES2114570T3 (es) 1991-10-22 1992-10-22 Utilizacion de derivados de prostaciclina para la inhibicion o el tratamiento de trastornos de la microcirculacion en el caso de la toma de agentes de contraste por rayos x, resonancia magnetica nuclear o ultrasonidos.

Country Status (11)

Country Link
US (1) US5814301A (enrdf_load_stackoverflow)
EP (1) EP0609336B1 (enrdf_load_stackoverflow)
JP (1) JPH07500585A (enrdf_load_stackoverflow)
AT (1) ATE162718T1 (enrdf_load_stackoverflow)
CA (1) CA2121838A1 (enrdf_load_stackoverflow)
DE (2) DE4135193C1 (enrdf_load_stackoverflow)
DK (1) DK0609336T3 (enrdf_load_stackoverflow)
ES (1) ES2114570T3 (enrdf_load_stackoverflow)
GR (1) GR3026324T3 (enrdf_load_stackoverflow)
PT (1) PT100997B (enrdf_load_stackoverflow)
WO (1) WO1993007875A1 (enrdf_load_stackoverflow)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4446694A1 (de) * 1994-12-09 1996-06-13 Schering Ag Verwendung von Zusätzen zu Kontrastmitteln zur Verbesserung der Bildgebung
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
CN1209751A (zh) * 1996-01-25 1999-03-03 舍林股份公司 血管内使用的改进的浓缩注射液和输注液
ATE262336T1 (de) * 1997-11-14 2004-04-15 United Therapeutics Corp Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa- 4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14- dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
WO2000076496A1 (fr) * 1999-06-14 2000-12-21 Toray Industries, Inc. Composes facilitant l'accumulation de medicaments dans des tissus tumoraux
US20020147223A1 (en) * 1999-06-14 2002-10-10 Hiroshi Maeda Agent for enhancing accumulation of drugs in tumor tissues
DE10115740A1 (de) 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
DE10244847A1 (de) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
EP1628654B2 (en) 2003-05-22 2019-12-04 United Therapeutics Corporation Compounds and methods for delivery of prostacyclin analogs
CN101287457B (zh) * 2004-04-12 2011-11-16 联合治疗公司 Treprostinil用于治疗神经性糖尿病的足部溃疡的用途
CA3212313A1 (en) 2013-03-14 2014-10-02 United Therapeutics Corporation Solid forms of treprostinil
MX2021001820A (es) * 2018-09-14 2021-04-28 Pharmosa Biopharm Inc Composicion farmaceutica para la liberacion controlada de farmacos acidos debiles y usos de los mismos.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2845770A1 (de) * 1978-10-19 1980-04-30 Schering Ag Neue prostacyclin-derivate und verfahren zu ihrer herstellung
DE3204443A1 (de) * 1982-02-08 1983-08-18 Schering Ag, 1000 Berlin Und 4619 Bergkamen Neue carbacycline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3448257C2 (en) * 1984-07-25 1988-08-18 Schering Ag, 1000 Berlin Und 4709 Bergkamen, De Cytoprotective action of prostacyclin derivatives on the kidney
US4820732A (en) * 1985-10-04 1989-04-11 The Upjohn Company Method and compositions for reducing dysfunction in angioplasty procedures
DE3608088C2 (de) * 1986-03-07 1995-11-16 Schering Ag Pharmazeutische Präparate, enthaltend Cyclodextrinclathrate von Carbacyclinderivaten
US4955878A (en) * 1986-04-04 1990-09-11 Biotechnology, Inc. Kit for preventing or treating arterial dysfunction resulting from angioplasty procedures
SE459806B (sv) * 1987-11-23 1989-08-07 Nils Enar Nilsson Anordning foer foerflyttning av en foersta del relativt en andra del
DE3740838A1 (de) * 1987-11-27 1989-06-08 Schering Ag Cyclodextrinclathrate von 5-cyano-prostacyclinderivaten und ihre verwendung als arzneimittel
CA2010511A1 (en) * 1989-03-01 1990-09-01 Roberto L. Ceriani Method of enhancing cancer therapy by administration of unsaturated fatty acids
JPH0669966B2 (ja) * 1989-07-05 1994-09-07 株式会社ミドリ十字 血管造影補助剤

Also Published As

Publication number Publication date
DK0609336T3 (da) 1998-09-21
PT100997B (pt) 1999-10-29
CA2121838A1 (en) 1993-04-29
US5814301A (en) 1998-09-29
EP0609336A1 (de) 1994-08-10
PT100997A (pt) 1994-01-31
EP0609336B1 (de) 1998-01-28
DE4135193C1 (enrdf_load_stackoverflow) 1993-03-11
WO1993007875A1 (de) 1993-04-29
JPH07500585A (ja) 1995-01-19
ATE162718T1 (de) 1998-02-15
GR3026324T3 (en) 1998-06-30
DE59209175D1 (de) 1998-03-05

Similar Documents

Publication Publication Date Title
NO2005019I1 (no) Metylaminolevulina, eventuelt i form av et salt, fortinnsvis metylaminolevulinat-hydroklorid
ES2114570T3 (es) Utilizacion de derivados de prostaciclina para la inhibicion o el tratamiento de trastornos de la microcirculacion en el caso de la toma de agentes de contraste por rayos x, resonancia magnetica nuclear o ultrasonidos.
ATE175201T1 (de) Mono-n-substituierte 1,4,7,10- tetraazacyclododecan-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
ITMI922964A1 (it) Formulazioni iniettabili acquose per radiodiagnostica comprendenti miscele di composti aromatici iodurati utili come agenti opacizzanti ai raggi x
SE9100342D0 (sv) Novel steroid esters
DE69401584D1 (de) Beta,beta-dimethyl-4-piperidinethanamin-derivate als inhibitoren der cholesterin-biosynthese
DE69216221D1 (de) Verbindungen mit guanidin-struktur und diese enthaltende pharmazeutische zusammensetzungen
NO964121L (no) Pyrimidin- eller triazin-karboksylsyrederivater for anvendelse som legemidler
BR0011440A (pt) Derivados de rodanina e seu uso na inibição e formação de imagens de amilóides
ITMI910658A1 (it) N-(4, 5-diidrossi-e 4, 5, 8-triidrossi-9, 10-diidro-9, 10-diosso-2- antracen-il)carbonil) amminoacidi utilizzabili nella terapia delle affezioni osteoarticolari
ATE169635T1 (de) Therapeutische verbindungen für die behandlung von krankheiten, die mit einem glutathion-defizit assoziiert sind, herstellungsprozess und diese enthaltene pharmazeutische zusammensetzungen
DE69413831D1 (de) Phenoxyphenylcyclopentenyl-hydroxyharnstoffe
BR9306870A (pt) Derivados farmacologicamente ativos de (aminometila terciária) - benzenometanol
NO951444D0 (no) Gestagent aktive 19,11-broede 4-östrener
KR930703013A (ko) 항당뇨병제로서 유용한 신규한 글루코하이드롤라제 억제제
HU9302188D0 (en) Method for producing acylamino-alkylidene-hydroxi-biphosphonic acid derivatives as well as one for producing medical preparatives containing said compounds
ATE160772T1 (de) Entzündungshemmende makrolactame (cyclamenol)
NO962248D0 (no) Joderte bifenylderivater og deres diagnostiske anvendelse
SE7700200L (sv) Forfarande for framstellning av karboxylsyraderivat av indan med anti-inflammatoriesk, analgetisk och antipyretisk aktivitet

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 609336

Country of ref document: ES